SREBF1 and metabolic dysfunction-associated steatotic liver disease: Therefore, our study identifies PPDPF as a negative regulator of lipogenesis by inhibiting mTOR-S6K-SREBP1 signaling and provides a promising therapeutic candidate for NAFLD.